165 related articles for article (PubMed ID: 25042014)
1. Ultralow doses of cannabinoid drugs protect the mouse brain from inflammation-induced cognitive damage.
Fishbein-Kaminietsky M; Gafni M; Sarne Y
J Neurosci Res; 2014 Dec; 92(12):1669-77. PubMed ID: 25042014
[TBL] [Abstract][Full Text] [Related]
2. Pre- and post-conditioning treatment with an ultra-low dose of Δ9-tetrahydrocannabinol (THC) protects against pentylenetetrazole (PTZ)-induced cognitive damage.
Assaf F; Fishbein M; Gafni M; Keren O; Sarne Y
Behav Brain Res; 2011 Jun; 220(1):194-201. PubMed ID: 21315768
[TBL] [Abstract][Full Text] [Related]
3. Additive antiemetic efficacy of low-doses of the cannabinoid CB(1/2) receptor agonist Δ(9)-THC with ultralow-doses of the vanilloid TRPV1 receptor agonist resiniferatoxin in the least shrew (Cryptotis parva).
Darmani NA; Chebolu S; Zhong W; Trinh C; McClanahan B; Brar RS
Eur J Pharmacol; 2014 Jan; 722():147-55. PubMed ID: 24157976
[TBL] [Abstract][Full Text] [Related]
4. Long-term cognitive deficits induced by a single, extremely low dose of tetrahydrocannabinol (THC): behavioral, pharmacological and biochemical studies in mice.
Senn R; Keren O; Hefetz A; Sarne Y
Pharmacol Biochem Behav; 2008 Jan; 88(3):230-7. PubMed ID: 17888506
[TBL] [Abstract][Full Text] [Related]
5. Biphasic effects of Δ9-tetrahydrocannabinol on brain stimulation reward and motor activity.
Katsidoni V; Kastellakis A; Panagis G
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2273-84. PubMed ID: 23830148
[TBL] [Abstract][Full Text] [Related]
6. Involvement of central and peripheral cannabinoid receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain.
Bagüés A; Martín MI; Sánchez-Robles EM
Eur J Pharmacol; 2014 Dec; 745():69-75. PubMed ID: 25446925
[TBL] [Abstract][Full Text] [Related]
7. Cortical neuroinflammation contributes to long-term cognitive dysfunctions following adolescent delta-9-tetrahydrocannabinol treatment in female rats.
Zamberletti E; Gabaglio M; Prini P; Rubino T; Parolaro D
Eur Neuropsychopharmacol; 2015 Dec; 25(12):2404-15. PubMed ID: 26499171
[TBL] [Abstract][Full Text] [Related]
8. The THC-induced suppression of Th1 polarization in response to Legionella pneumophila infection is not mediated by increases in corticosterone and PGE2.
Newton CA; Lu T; Nazian SJ; Perkins I; Friedman H; Klein TW
J Leukoc Biol; 2004 Oct; 76(4):854-61. PubMed ID: 15258190
[TBL] [Abstract][Full Text] [Related]
9. Beneficial and deleterious effects of cannabinoids in the brain: the case of ultra-low dose THC.
Sarne Y
Am J Drug Alcohol Abuse; 2019; 45(6):551-562. PubMed ID: 30864864
[TBL] [Abstract][Full Text] [Related]
10. Contrasting effects of different cannabinoid receptor ligands on mouse ingestive behaviour.
Grey J; Terry P; Higgs S
Behav Pharmacol; 2012 Sep; 23(5-6):551-9. PubMed ID: 22772336
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of selective cannabinoid CB(1) and CB(2) receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis.
Tambaro S; Casu MA; Mastinu A; Lazzari P
Eur J Pharmacol; 2014 Apr; 729():67-74. PubMed ID: 24561047
[TBL] [Abstract][Full Text] [Related]
12. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice.
Myers AM; Siegele PB; Foss JD; Tuma RF; Ward SJ
Br J Pharmacol; 2019 May; 176(10):1552-1567. PubMed ID: 29338068
[TBL] [Abstract][Full Text] [Related]
13. Effect of ACEA--a selective cannabinoid CB1 receptor agonist on the protective action of different antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model.
Andres-Mach M; Zolkowska D; Barcicka-Klosowska B; Haratym-Maj A; Florek-Luszczki M; Luszczki JJ
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):301-9. PubMed ID: 22789660
[TBL] [Abstract][Full Text] [Related]
14. Arachidonyl-2'-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model.
Luszczki JJ; Czuczwar P; Cioczek-Czuczwar A; Czuczwar SJ
Eur J Pharmacol; 2006 Oct; 547(1-3):65-74. PubMed ID: 16930590
[TBL] [Abstract][Full Text] [Related]
15. Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.
Klumpers LE; Roy C; Ferron G; Turpault S; Poitiers F; Pinquier JL; van Hasselt JG; Zuurman L; Erwich FA; van Gerven JM
Br J Clin Pharmacol; 2013 Jul; 76(1):65-77. PubMed ID: 23278647
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid receptor-mediated regulation of intracellular calcium by delta(9)-tetrahydrocannabinol in resting T cells.
Rao GK; Zhang W; Kaminski NE
J Leukoc Biol; 2004 May; 75(5):884-92. PubMed ID: 14966196
[TBL] [Abstract][Full Text] [Related]
17. Δ
Shang VC; Kendall DA; Roberts RE
Biochem Pharmacol; 2016 Nov; 120():63-71. PubMed ID: 27641813
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors.
Gaffal E; Cron M; Glodde N; Tüting T
Allergy; 2013 Aug; 68(8):994-1000. PubMed ID: 23889474
[TBL] [Abstract][Full Text] [Related]
19. Δ(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice.
Paronis CA; Nikas SP; Shukla VG; Makriyannis A
Behav Pharmacol; 2012 Dec; 23(8):802-5. PubMed ID: 23075707
[TBL] [Abstract][Full Text] [Related]
20. Long-term behavioral and biochemical effects of an ultra-low dose of Δ9-tetrahydrocannabinol (THC): neuroprotection and ERK signaling.
Fishbein M; Gov S; Assaf F; Gafni M; Keren O; Sarne Y
Exp Brain Res; 2012 Sep; 221(4):437-48. PubMed ID: 22821081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
